In tough competition with other innovative start-up companies, ArgusEye is granted 900 000 SEK from Vinnova’s program Innovative Startups Step 2.
In September 2017, ArgusEye received a grant through Vinnova’s program Innovative Startups Step 1. The grant allowed ArgusEye to conduct a market analysis to get a better understanding of problems associated with current techniques used in the production of biological pharmaceuticals and to develop sensor systems that addresses some of these problems. Since the project was successfully completed, it was possibly to apply also for funding for Step 2.
Gladly, ArgusEye’s application received positive response and the project was granted funding. The project has a total budget of 1 M SEK where the goal is to develop a new prototype that is optimized for large scale production of biological drugs and to carry out a comprehensive technical validation of the developed prototype.
– The project enables us to validate our sensor technology in large scale pharmaceutical production, which will give us extensive technical knowledge about our system. Knowledge that will be very important for future product development as well as for an expanded customer dialogue, says Erik Martinsson, CEO of ArgusEye.
The technical validation will be carried out at the newly opened TESTA center in Uppsala, where small companies and researchers can scale up and evaluate innovative products for biological drug development.
Press Release (in Swedish)